JP7583515B2 - ＴＮＦα拮抗薬を使用したドライアイ疾患の治療方法 - Google Patents

ＴＮＦα拮抗薬を使用したドライアイ疾患の治療方法 Download PDF

Info

Publication number
JP7583515B2
JP7583515B2 JP2018566485A JP2018566485A JP7583515B2 JP 7583515 B2 JP7583515 B2 JP 7583515B2 JP 2018566485 A JP2018566485 A JP 2018566485A JP 2018566485 A JP2018566485 A JP 2018566485A JP 7583515 B2 JP7583515 B2 JP 7583515B2
Authority
JP
Japan
Prior art keywords
seq
ded
tnfα
patient
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018566485A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019520355A5 (enExample
JP2019520355A (ja
Inventor
ヘ，ユンシェン
リースナー，クリスチャン
ワルド，マイケル
ワイスガーバー，ジョージ
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2019520355A publication Critical patent/JP2019520355A/ja
Publication of JP2019520355A5 publication Critical patent/JP2019520355A5/ja
Priority to JP2022121796A priority Critical patent/JP2022169546A/ja
Application granted granted Critical
Publication of JP7583515B2 publication Critical patent/JP7583515B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2018566485A 2016-06-20 2017-06-19 ＴＮＦα拮抗薬を使用したドライアイ疾患の治療方法 Active JP7583515B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022121796A JP2022169546A (ja) 2016-06-20 2022-07-29 ＴＮＦα拮抗薬を使用したドライアイ疾患の治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662352091P 2016-06-20 2016-06-20
US62/352,091 2016-06-20
PCT/IB2017/053625 WO2017221128A1 (en) 2016-06-20 2017-06-19 Methods of treating dry eye disease using tnf alpha antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022121796A Division JP2022169546A (ja) 2016-06-20 2022-07-29 ＴＮＦα拮抗薬を使用したドライアイ疾患の治療方法

Publications (3)

Publication Number Publication Date
JP2019520355A JP2019520355A (ja) 2019-07-18
JP2019520355A5 JP2019520355A5 (enExample) 2020-07-30
JP7583515B2 true JP7583515B2 (ja) 2024-11-14

Family

ID=59285284

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018566485A Active JP7583515B2 (ja) 2016-06-20 2017-06-19 ＴＮＦα拮抗薬を使用したドライアイ疾患の治療方法
JP2022121796A Pending JP2022169546A (ja) 2016-06-20 2022-07-29 ＴＮＦα拮抗薬を使用したドライアイ疾患の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022121796A Pending JP2022169546A (ja) 2016-06-20 2022-07-29 ＴＮＦα拮抗薬を使用したドライアイ疾患の治療方法

Country Status (6)

Country Link
US (2) US12146187B2 (enExample)
EP (1) EP3472203A1 (enExample)
JP (2) JP7583515B2 (enExample)
CN (1) CN109311976A (enExample)
CA (1) CA3032790A1 (enExample)
WO (1) WO2017221128A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12146187B2 (en) * 2016-06-20 2024-11-19 Novartis Ag Methods of treating dry eye disease using TNF alpha antagonists
CN114075597A (zh) * 2020-08-12 2022-02-22 深圳市坪山区人民医院 用于sle易感基因snp检测的核酸组合物、试剂盒及其使用方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009052140A1 (en) 2007-10-15 2009-04-23 Alcon Research, Ltd. Use of tnf receptor antagonists for treating dry eye
JP2013544078A (ja) 2010-10-22 2013-12-12 エスバテック − ア ノバルティス カンパニー エルエルシー 安定で可溶性の抗体
JP2015525237A (ja) 2012-06-21 2015-09-03 ハノル バイオファーマ カンパニー リミテッドＨａｎａｌｌ Ｂｉｏｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． 変形されたヒト腫瘍壊死因子受容体−１ポリペプチドの新規用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818537A (en) 1986-10-21 1989-04-04 Liposome Technology, Inc. Liposome composition for treating dry eye
US5041434A (en) 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
US5958912A (en) 1992-04-21 1999-09-28 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β
US5290572A (en) 1992-08-06 1994-03-01 Deo Corporation Opthalmic composition for treating dry eye
US5696166A (en) 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
WO1997020578A1 (en) 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
CN1114401C (zh) 1998-07-14 2003-07-16 阿尔康实验室公司 11－(3－二甲氨基亚丙基)－6,11－二氢二苯并[b,e]噁庚英－2－乙酸用于制药的新用途
MX345039B (es) 2008-06-25 2017-01-16 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles que inhiben el tnfa.
US12146187B2 (en) * 2016-06-20 2024-11-19 Novartis Ag Methods of treating dry eye disease using TNF alpha antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009052140A1 (en) 2007-10-15 2009-04-23 Alcon Research, Ltd. Use of tnf receptor antagonists for treating dry eye
JP2013544078A (ja) 2010-10-22 2013-12-12 エスバテック − ア ノバルティス カンパニー エルエルシー 安定で可溶性の抗体
JP2015525237A (ja) 2012-06-21 2015-09-03 ハノル バイオファーマ カンパニー リミテッドＨａｎａｌｌ Ｂｉｏｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． 変形されたヒト腫瘍壊死因子受容体−１ポリペプチドの新規用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ｉｎｖｅｓｔ Ｏｐｈｔｈａｌｍｏｌ Ｖｉｓ Ｓｃｉ．， ２０１３， Ｖｏｌ．５４， ｐｐ． ７５５７－７５６６
Ｓｃｉ Ｔｒａｎｓｌ Ｍｅｄ． ２０１５ Ｊｕｎｅ １０； ７（２９１）： ２９１ｒａ９３， ｐｐ． １－１０

Also Published As

Publication number Publication date
JP2022169546A (ja) 2022-11-09
WO2017221128A1 (en) 2017-12-28
US20250129414A1 (en) 2025-04-24
US20190177407A1 (en) 2019-06-13
US12146187B2 (en) 2024-11-19
CA3032790A1 (en) 2017-12-28
CN109311976A (zh) 2019-02-05
EP3472203A1 (en) 2019-04-24
JP2019520355A (ja) 2019-07-18

Similar Documents

Publication Publication Date Title
US11725246B2 (en) Methods of treating ophthalmic disorders
AU2012341081B2 (en) Methods of treating psoriatic arthritis (PsA) using IL-17 antagonists and PsA response or non- response alleles
EP3129497B1 (en) Methods of selectively treating asthma using il-13 antagonists
US20250129414A1 (en) Methods of treating dry eye disease using tnf alpha antagonists
US20150125462A1 (en) Methods of treating ankylosing spondylitis using il-17 antagonists
TW201307845A (zh) 預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法
WO2014155278A2 (en) Methods of treating autoimmune diseases using il-17 antagonists
JP2018517721A (ja) 原発性巣状分節性糸球体硬化症を処置する方法
JP2023516497A (ja) Ｉｌ３３にリスクアレルを有する対象を治療するための治療方法
US20110034345A1 (en) Methods for diagnosis of maculopathies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200618

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200618

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210622

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220729

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220729

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220809

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220915

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220920

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20221007

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20221018

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240826

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241101

R150 Certificate of patent or registration of utility model

Ref document number: 7583515

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150